Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. McDermott · SciRah

Researcher profile · Semantic Scholar

M. McDermott

Share profile

M. McDermott — researcher profile on SciRah

h-index: 18
Works: 70
Citations: 1,318

Most-cited papers

In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
M. McDermott, A. Eustace, Steven Busschots, L. Breen +4 more
2014Frontiers in Oncology302 citations Open access
Semantic Scholar
CDK8/19 Mediator kinases potentiate induction of transcription by NFκB
Mengqian Chen, Jiaxin Liang, Hao Ji, Zhengguan Yang +13 more
2017Proceedings of the National Academy of Sciences of the United States of America120 citations Open access
Semantic Scholar
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
N. O'Brien, M. McDermott, D. Conklin, Tong Luo +12 more
2020Breast Cancer Research117 citations Open access
Semantic Scholar
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer
M. McDermott, A. Chumanevich, C. Lim, Jiaxin Liang +9 more
2017OncoTarget116 citations Open access
Semantic Scholar
Concise total syntheses of (–)-Jorunnamycin A and (–)-Jorumycin enabled by asymmetric catalysis
E. Welin, Aurapat Ngamnithiporn, Max Klatte, G. Lapointe +13 more
2018Science87 citations Open access
Semantic Scholar
Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer
E. Broude, Balázs Győrffy, A. Chumanevich, Mengqian Chen +4 more
2015Current Cancer Drug Targets83 citations Open access
Semantic Scholar
Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.
S. Rani, C. Corcoran, L. Shiels, S. Germano +9 more
2014Cancer Research49 citations
Semantic Scholar
Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
M. McDermott, N. O'Brien, Benjamin Hoffstrom, Ke Gong +16 more
2023Clinical Cancer Research47 citations Open access
Semantic Scholar
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
M. McDermott, B. Browne, N. Conlon, N. O'Brien +7 more
2014Molecular Cancer46 citations Open access
Semantic Scholar
HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
M. McDermott, N. Conlon, B. Browne, A. Szabo +5 more
2019Cancers42 citations Open access
Semantic Scholar
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
B. Browne, A. Eustace, S. Kennedy, N. O'Brien +11 more
2012Breast Cancer Research and Treatment41 citations
Semantic Scholar
Inhibition of CDK8/19 Mediator kinase potentiates HER2-targeting drugs and bypasses resistance to these agents in vitro and in vivo
Xiaokai Ding, Amanda C. Sharko, M. McDermott, G. Schools +14 more
2022Proceedings of the National Academy of Sciences of the United States of America34 citations Open access
Semantic Scholar
CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition
M. McDermott, Amanda C. Sharko, Jessica Munie, Susannah Kassler +3 more
2020Cells34 citations Open access
Semantic Scholar
The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
Amanda C. Sharko, C. Lim, M. McDermott, C. Hennes +5 more
2021Cells29 citations Open access
Semantic Scholar
Tucatinib has Selective Activity in HER2-Positive Cancers and Significant Combined Activity with Approved and Novel Breast Cancer-Targeted Therapies.
N. O'Brien, Holly K T Huang, M. McDermott, Athena M. Madrid +7 more
2022Molecular Cancer Therapeutics26 citations Open access
Semantic Scholar
Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL
A. Eustace, N. Conlon, M. McDermott, B. Browne +18 more
2018BMC Cancer26 citations Open access
Semantic Scholar
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
M. McDermott, A. Canonici, L. Ivers, B. Browne +4 more
2017International Journal of Oncology26 citations Open access
Semantic Scholar
Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
M. Fejzo, Hsiao-Wang Chen, L. Anderson, M. McDermott +3 more
2020Gynecologic Oncology23 citations Open access
Semantic Scholar
Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-drug Conjugate for Treatment of CLDN18.2 Positive Cancers.
N. O'Brien, M. McDermott, Jun Zhang, Ke Gong +11 more
2023Molecular Cancer Therapeutics16 citations
Semantic Scholar
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapy
N. Gaynor, A. Blanco, S. Madden, B. Moran +12 more
2023British Journal of Cancer14 citations Open access
Semantic Scholar
Effect of afatinib alone and in combination with trastuzumab in HER2-positive breast cancer cell lines.
A. Canonici, Kasper Pedersen, B. Browne, M. McDermott +3 more
20129 citations
Semantic Scholar
Peer Review #1 of "Synthesis and biological evaluation of small molecule modulators of CDK8/Cyclin C complex with phenylaminoquinoline scaffold (v0.1)"
M. Al-Sanea, A. Abdelazem, M. Al-Sanea, B. Park +186 more
20205 citations Open access
Semantic Scholar
Abstract P6-17-11: The small molecule inhibitor of HER2, tucatinib, has potent and highly selective activity in preclinical modes of HER2-driven cancer
N. O'Brien, D. Conklin, M. McDermott, Tong Luo +5 more
2019Poster Session Abstracts4 citations
Semantic Scholar
Mechanisms of resistance to lapatinib in HER2 positive breast cancer
M. McDermott
20124 citations
Semantic Scholar
Irreversible panHER tyrosine kinase inhibitors (TKIs) to induce irreversible senescence in HER2 positive breast cancer cells.
M. McDermott, B. Browne, A. Szabo, J. Crown +1 more
20163 citations
Semantic Scholar
Lapatinib-induced senescent-like phenotype in HER2-positive breast cancer cells.
M. McDermott, B. Browne, J. Crown, N. O'Brien +2 more
2011Journal of Clinical Oncology3 citations
Semantic Scholar
Abstract 3825: Targeting activated PI3K/mTOR signaling overcomes resistance to CDK4/6-based therapies in preclinical ER+ breast cancer models
N. O'Brien, M. McDermott, D. Conklin, A. Gaither +11 more
2019Experimental and Molecular Therapeutics2 citations
Semantic Scholar
Abstract P3-07-05: CDK8 inhibition improves the efficacy of ER- and HER2-targeted drugs in breast cancer
M. McDermott, A. Chumanevich, J. Liang, M. Chen +4 more
20172 citations
Semantic Scholar
Abstract 5634: Increased co-amplification of HER2 and STARD3 in a cell line model of acquired lapatinib resistance.
M. McDermott, L. Anderson, L. Shields, N. O'Brien +8 more
20132 citations
Semantic Scholar
Effect of acquired resistance to lapatinib in HER2-positive breast cancer cells on the Bcl-2 family members MCL-1 and BAX.
A. Eustace, B. Browne, S. Madden, L. O'Driscoll +6 more
20122 citations
Semantic Scholar
Abstract 3023: Fatty acid synthase (FASN) inhibitors synergize with carfilzomib (CFZ) in acute myeloid leukemia (AML) and multiple myeloma (MM)
M. Peng, Sanaz N. Ghafouri, M. McDermott, D. Slamon +1 more
2022Cancer Research1 citations
Semantic Scholar
Abstract 2336: Pan-cancer analysis of NAMPT inhibitors reveals unique sensitivities to multiple NAMPT inhibitors in several cancer types
Jenny Hong, M. McDermott, Jewel Ng, Prita Pandya +1 more
2022Cancer Research1 citations
Semantic Scholar
Abstract 342: Development and characterization of a novel anti-CLDN6 antibody drug conjugate for the treatment of CLDN6 positive cancers
M. McDermott, Ke Gong, N. O'Brien, D. Conklin +15 more
2022Cancer Research1 citations
Semantic Scholar
Abstract LB132: CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+ breast cancer via STAT1 and STAT3
Xiaokai Ding, Amanda C. Sharko, M. McDermott, Hao Ji +11 more
2021Experimental and Molecular Therapeutics1 citations
Semantic Scholar
Pre-clinical evaluation of the PP2A inhibitor LB-100 for the treatment of lapatinib resistant HER2-positive breast cancer.
N. Conlon, M. McDermott, B. Browne, S. Roche +6 more
20181 citations
Semantic Scholar
Abstract 1512: Functional characterization of novel transcription-regulating cancer drug targets, CDK8 and CDK19, using CRISPR/Cas9 knockout and a highly selective CDK8/19 kinase inhibitor
Mengqian Chen, Bing Hu, Hao Ji, S. Altilia +6 more
20171 citations
Semantic Scholar
HER2 Targeted Monoclonal Antibodies and Tyrosine Kinase Inhibitors
N. O'Brien, A. Canonici, K. Howe, M. McDermott +4 more
20141 citations Open access
Semantic Scholar
144 Alterations in Apoptosis-related Genes in Cell Line Models of Acquired Lapatinib Resistance, Identifies Potential Therapeutic Targets for the Treatment of Lapatinib Resistant HER2-positive Breast Cancer
A. Eustace, B. Browne, M. McDermott, P. O'Leary +6 more
20121 citations Open access
Semantic Scholar
145 PP2A – a Novel Target for the Treatment of Lapatinib-resistant Breast Cancer
M. McDermott, B. Browne, N. O'Brien, D. Slamon +6 more
20121 citations
Semantic Scholar
Abstract P4-01-06: The Role of the PI3K/AKT, RAS/MAPK and Novel Signaling Pathways in Resistance to HER2-Targeted Therapy
N. O'Brien, K. Wilcox, M. McDermott, J. Crown +2 more
20101 citations
Semantic Scholar
Topoisomerase-Based CDH17 Antibody Drug Conjugates Overcome P-gp Resistance but Undergo Target Mediated Clearance in Colorectal Cancer.
N. O'Brien, Jun Zhang, Ke Gong, M. McDermott +11 more
2026Clinical Cancer Research0 citations Open access
Semantic Scholar
Inhibition of Acetyl-CoA-carboxylase induces endoplasmic reticulum stress and augments the efficacy of anti-cancer therapies.
N. Shan, Henriette U. Balinda, J. Dai, Yueyue Wang +15 more
2026Clinical Cancer Research0 citations
Semantic Scholar
Abstract 6258: The discovery and preclinical characterization of the potent covalent KRASG12C inhibitor UCT-001024
Tristin E. Rose, B. O’Boyle, Justin A. Hilf, E. L. Baker-Tripp +13 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 6254: The discovery and preclinical characterization of the SAM-competitive PRMT5 inhibitor UCT-000445
M. McDermott, N. O'Brien, B. O’Boyle, M. Bartberger +11 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 5991: Development and characterization of a novel CDK4/6 inhibitor for the treatment of CDK4/6 dependent cancers
N. O'Brien, M. McDermott, B. O’Boyle, Justin A. Hilf +10 more
2023Cancer Research0 citations
Semantic Scholar
Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
M. McDermott, B. Browne, N. Conlon, N. O'Brien +7 more
2023Molecular Cancer0 citations Open access
Semantic Scholar
Abstract 4044: Development of UCT-01-097, a novel orally available ERK1/2 inhibitor for the treatment of ERK1/2 dependent cancers
N. O'Brien, M. McDermott, B. O’Boyle, Corey M. Reeves +12 more
2023Cancer Research0 citations
Semantic Scholar
Abstract 332: Development of a novel therapeutic CLDN18.2 monoclonal antibody and antibody drug conjugate for the treatment of CLDN18.2 positive cancers
N. O'Brien, M. McDermott, Jun Zhang, Ke Gong +10 more
2022Cancer Research0 citations
Semantic Scholar
Abstract LB197: Tucatinib has selective activity in HER2-positive cancers and significant combined activity with approved and novel breast cancer targeted therapies
N. O'Brien, Holly K T Huang, M. McDermott, Athena M. Madrid +7 more
2022Cancer Research0 citations
Semantic Scholar
570P Hypomethylating agents synergistically combine with PARP inhibitors in ovarian cancer
J. J. Hong, M. Vernon, P. Pandya, M. McDermott +2 more
2022Annals of Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. O'Brien×26
Invite
N. O'Brien — researcher profile on SciRah
D. Slamon×21
Invite
D. Slamon — researcher profile on SciRah
J. Crown×20
Invite
J. Crown — researcher profile on SciRah
N. O'Donovan×19
Invite
N. O'Donovan — researcher profile on SciRah

×15

Invite

B. Browne — researcher profile on SciRah

Invite

Tong Luo — researcher profile on SciRah

Invite

Raul Ayala — researcher profile on SciRah

Invite

E. Broude — researcher profile on SciRah

Invite

I. Roninson — researcher profile on SciRah

Invite

Kevin Chau — researcher profile on SciRah

Invite

A. Eustace — researcher profile on SciRah

Mengqian Chen×6

Invite

Mengqian Chen — researcher profile on SciRah